HSPA1A and neoplasm: We sought to target this potential vulnerability in PDAC by leveraging a uniquely acting HSP70 inhibitor, AP-4-139B (also ‘139B’), that targets HSP70 in multiple compartments of tumor cells including the mitochondria [17].